Susquehanna Fundamental Investments’s Coherus Oncology CHRS Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$63.6K	Sell	36,748 -109,483	-75%	-$220K	﹤0.01%	910
2024 Q1	$349K	Buy	+146,231	New	+$360K	0.02%	525
2023 Q4	–	Sell	-40,694	Closed	-$152K	–	122
2023 Q3	$152K	Sell	40,694 -37,054	-48%	-$171K	0.01%	337
2023 Q2	$332K	Hold	77,748	–	–	0.01%	500
2023 Q1	$532K	Sell	77,748 -5,027	-6%	-$39K	0.01%	665
2022 Q4	$656K	Buy	+82,775	New	+$637K	0.01%	780
2022 Q1	–	Sell	-67,518	Closed	-$1.08M	–	1554
2021 Q4	$1.08M	Buy	67,518 +14,978	+29%	+$262K	0.03%	620
2021 Q3	$844K	Sell	52,540 -33,129	-39%	-$486K	0.02%	942
2021 Q2	$1.19M	Buy	85,669 +60,474	+240%	+$856K	0.02%	780
2021 Q1	$368K	Buy	+25,195	New	+$428K	0.01%	1239

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna Fundamental Investments's CHRS Position: Q2 2024 in Review

Susquehanna Fundamental Investments reduced its Coherus Oncology (CHRS) stake by 75% in Q2 2024, selling an estimated $220K and leaving 36,748 shares worth $63.6K. The position accounts for ﹤0.01% of the portfolio, ranked #910.

Susquehanna Fundamental Investments first reported a position in CHRS in Q1 2021 and has held it in 10 quarters since. The position peaked at $1.19M in Q2 2021. 135 funds tracked by Wall St. Rank hold CHRS as of Q2 2024.

Susquehanna Fundamental Investments held 36,748 shares of Coherus Oncology worth $63.6K as of Q2 2024.
Susquehanna Fundamental Investments sold 109,483 Coherus Oncology shares in Q2 2024, an estimated $220K.
Coherus Oncology made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q2 2024, its #910 holding.
Susquehanna Fundamental Investments first reported a position in Coherus Oncology in Q1 2021 and has held it in 10 quarters since.
Susquehanna Fundamental Investments's Coherus Oncology position peaked at $1.19M in Q2 2021.
135 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2024.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2024, filed 15 Aug 2024.